nach oben

Heart and Vessels

Erschienen in:

30.03.2022 | Original Article

Relation of glucose variability to vulnerable plaque formation in patients with coronary artery disease

verfasst von: Kazuya Tateishi, Yuichi Saito, Hideki Kitahara, Yoshio Kobayashi

Erschienen in: Heart and Vessels | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Although glucose variability (GV) is reportedly associated with coronary plaque vulnerability, namely lipid-rich plaque, details are not fully understood. The aim of this study was to evaluate relations of GV after discharge to vulnerable plaque formation assessed by near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) in patients with and without diabetes.

Methods

A total of 40 patients undergoing percutaneous coronary intervention under NIRS-IVUS guidance were included, among whom 13 (33%) had diabetes and 20 (50%) presented with acute myocardial infarction (MI). GV was evaluated by a flush glucose monitoring system, primarily with mean amplitude of glycemic excursion (MAGE). Lipid-rich plaque was assessed by maximum lipid core burden index in 4 mm (maxLCBI_4mm) in the target lesion using NIRS-IVUS.

Results

Mean MAGE and maxLCBI_4mm were 69.7 ± 25.6 mg/dl and 508.0 ± 294.9. Intra-day GV was not significantly associated with maxLCBI_4mm in the entire study population, while MAGE was correlated with maxLCBI_4mm in non-diabetic patients (r = 0.46, p = 0.02). In patients with and without acute MI presentation, no significant relations were found between MAGE and maxLCBI_4mm.

Conclusion

GV was associated with lipid core plaque formation, especially in non-diabetic patients.

Nallamothu BK, Normand SL, Wang Y, Hofer TP, Brush JE Jr, Messenger JC, Bradley EH, Rumsfeld JS, Krumholz HM (2015) Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study. Lancet 385:1114–1122CrossRef

Ozaki Y, Katagiri Y, Onuma Y, Amano T, Muramatsu T, Kozuma K, Otsuji S, Ueno T, Shiode N, Kawai K, Tanaka N, Ueda K, Akasaka T, Hanaoka KI et al (2018) CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018. Cardiovasc Interv Ther 33:178–203CrossRef

GBD (2013) Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–171

Bom MJ, van der Heijden DJ, Kedhi E, van der Heyden J, Meuwissen M, Knaapen P, Timmer SAJ, van Royen N (2017) Early detection and treatment of the vulnerable coronary plaque: can we prevent acute coronary syndromes? Circ Cardiovasc Imaging 10:e005973CrossRef

Pasterkamp G, den Ruijter HM, Libby P (2017) Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. Nat Rev Cardiol 14:21–29CrossRef

Amano T, Matsubara T, Uetani T, Nanki M, Marui N, Kato M, Yoshida T, Arai K, Yokoi K, Ando H, Kumagai S, Ishii H, Izawa H, Hotta N, Murohara T (2008) Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance. JACC Cardiovasc Imaging 1:39–45CrossRef

Inaba S, Okayama H, Funada J, Higashi H, Saito M, Yoshii T, Hiasa G, Sumimoto T, Takata Y, Nishimura K, Inoue K, Ogimoto A, Higaki J (2012) Impact of type 2 diabetes on serial changes in tissue characteristics of coronary plaques: an integrated backscatter intravascular ultrasound analysis. Eur Heart J Cardiovasc Imaging 13:717–723CrossRef

Kuroda M, Shinke T, Sakaguchi K, Otake H, Takaya T, Hirota Y, Sugiyama D, Nakagawa M, Hariki H, Inoue T, Osue T, Taniguchi Y, Iwasaki M, Nishio R, Kinutani H, Konishi A, Hiranuma N, Takahashi H, Terashita D, Hirata KI (2015) Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy: a prospective observational study. JACC Cardiovasc Interv 8:800–811CrossRef

Okada K, Hibi K, Gohbara M, Kataoka S, Takano K, Akiyama E, Matsuzawa Y, Saka K, Maejima N, Endo M, Iwahashi N, Tsukahara K, Kosuge M, Ebina T, Fitzgerald PJ, Honda Y, Umemura S, Kimura K (2015) Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes. Cardiovasc Diabetol 14:111CrossRef

10.

Gohbara M, Hibi K, Mitsuhashi T, Maejima N, Iwahashi N, Kataoka S, Akiyama E, Tsukahara K, Kosuge M, Ebina T, Umemura S, Kimura K (2016) Glycemic variability on continuous glucose monitoring system correlates with non-culprit vessel coronary plaque vulnerability in patients with first-episode acute coronary syndrome - optical coherence tomography study. Circ J 80:202–210CrossRef

11.

Gardner CM, Tan H, Hull EL, Lisauskas JB, Sum ST, Meese TM, Jiang C, Madden SP, Caplan JD, Burke AP, Virmani R, Goldstein J, Muller JE (2008) Detection of lipid core coronary plaques in autopsy specimens with a novel catheter-based near-infrared spectroscopy system. JACC Cardiovasc Imaging 1:638–648CrossRef

12.

Mori N, Saito Y, Saito K, Matsuoka T, Tateishi K, Kadohira T, Kitahara H, Fujimoto Y, Kobayashi Y (2020) Relation of plasma xanthine oxidoreductase activity to coronary lipid core plaques assessed by near-infrared spectroscopy intravascular ultrasound in patients with stable coronary artery disease. Am J Cardiol 125:1006–1012CrossRef

13.

Tateishi K, Kitahara H, Saito Y, Kadohira T, Saito K, Matsuoka T, Mori N, Nakayama T, Fujimoto Y, Kobayashi Y (2021) Impact of clinical presentations on lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound. Int J Cardiovasc Imaging 37:1151–1158CrossRef

14.

Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R (2016) Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388:2254–2263CrossRef

15.

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction (2018) Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 72:2231–2264CrossRef

16.

Suzuki N, Asano T, Nakazawa G, Aoki J, Tanabe K, Hibi K, Ikari Y, Kozuma K (2020) Clinical expert consensus document on quantitative coronary angiography from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther 35:105–116CrossRef

17.

Saito Y, Mori N, Murase T, Nakamura T, Akari S, Saito K, Matsuoka T, Tateishi K, Kadohira T, Kitahara H, Fujimoto Y, Kobayashi Y (2021) Greater coronary lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound in patients with elevated xanthine oxidoreductase: a mechanistic insight. Heart Vessels 36:597–604CrossRef

18.

Saito Y, Kobayashi Y, Fujii K, Sonoda S, Tsujita K, Hibi K, Morino Y, Okura H, Ikari Y, Honye J (2022) Clinical expert consensus document on intravascular ultrasound from the Japanese Association of Cardiovascular Intervention and Therapeutics (2021). Cardiovasc Interv Ther 37:40–51CrossRef

19.

Sonoda S, Hibi K, Okura H, Fujii K, Honda Y, Kobayashi Y (2020) Current clinical use of intravascular ultrasound imaging to guide percutaneous coronary interventions. Cardiovasc Interv Ther 35:30–36CrossRef

20.

Mintz GS (2020) Intravascular ultrasound guidance improves patient survival (mortality) after drug-eluting stent implantation: review and updated bibliography. Cardiovasc Interv Ther 35:37–43CrossRef

21.

American Diabetes Association (2020) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 43:S14–S31CrossRef

22.

Kovatchev B, Cobelli C (2016) Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care 39:502–510CrossRef

23.

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42:1593–1603CrossRef

24.

Zhou Z, Sun B, Huang S, Zhu C, Bian M (2020) Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovasc Diabetol 19:102CrossRef

25.

EasyGV. http://www.phc.ox.ac.uk/research/diabetes/software/easygv. Accessed 22 Feb 2022.

26.

Waksman R, Di Mario C, Torguson R, Ali ZA, Singh V, Skinner WH, Artis AK, Cate TT, Powers E, Kim C, Regar E, Wong SC, Lewis S, Wykrzykowska J, Dube S, Kazziha S, van der Ent M, Shah P, Craig PE, Zou Q, Kolm P, Brewer HB, Garcia-Garcia HM, Investigators LRP (2019) Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet 394:1629–1637CrossRef

27.

Erlinge D, Maehara A, Ben-Yehuda O, Bøtker HE, Maeng M, Kjøller-Hansen L, Engstrøm T, Matsumura M, Crowley A, Dressler O, Mintz GS, Fröbert O, Persson J, Wiseth R, Larsen AI, Okkels Jensen L, Nordrehaug JE, Bleie Ø, Omerovic E, Held C, James SK, Ali ZA, Muller JE, Stone GW, Investigators PROSPECTII (2021) Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet 397:985–995CrossRef

28.

Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S (2015) The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther 17:787–794CrossRef

29.

Tateishi K, Saito Y, Kitahara H, Kobayashi Y (2022) Impact of glycemic variability on coronary and peripheral endothelial dysfunction in patients with coronary artery disease. J Cardiol 79:65–70CrossRef

30.

Ito T, Ichihashi T, Fujita H, Sugiura T, Yamamoto J, Kitada S, Nakasuka K, Kawada Y, Ohte N (2019) The impact of intraday glucose variability on coronary artery spasm in patients with dysglycemia. Heart Vessels 34:1250–1257CrossRef

31.

Ishihara M (2012) Acute hyperglycemia in patients with acute myocardial infarction. Circ J 76:563–571CrossRef

32.

Oswald GA, Corcoran S, Yudkin JS (1984) Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1:1264–1267CrossRef

33.

Mi SH, Su G, Yang HX, Zhou Y, Tian L, Zhang T, Tao H (2017) Comparison of in-hospital glycemic variability and admission blood glucose in predicting short-term outcomes in non-diabetes patients with ST elevation myocardial infarction underwent percutaneous coronary intervention. Diabetol Metab Syndr 9:20CrossRef

34.

Pu Z, Lai L, Yang X, Wang Y, Dong P, Wang D, Xie Y, Han Z (2020) Acute glycemic variability on admission predicts the prognosis in hospitalized patients with coronary artery disease: a meta-analysis. Endocrine 67:526–534CrossRef

35.

Park SE, Lee BW, Kim JH, Lee WJ, Cho JH, Jung CH, Lee SH, Suh S, Hur GC, Kim SH, Jang YH et al (2017) Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study). Diabetes Obes Metab 19:892–896CrossRef

36.

Lee S, Lee H, Kim Y, Kim E (2019) Effect of DPP-IV inhibitors on glycemic variability in patients with T2DM: a systematic review and meta-analysis. Sci Rep 9:13296CrossRef

37.

Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687CrossRef

38.

Teraguchi I, Imanishi T, Ozaki Y, Tanimoto T, Ueyama M, Orii M, Shiono Y, Shimamura K, Ishibashi K, Yamano T, Ino Y, Yamaguchi T, Hirata K, Kubo T, Sanke T, Akasaka T (2014) Acute-phase glucose fluctuation is negatively correlated with myocardial salvage after acute myocardial infarction. Circ J 78:170–179CrossRef

39.

Koska J, Saremi A, Howell S, Bahn G, De Courten B, Ginsberg H, Beisswenger PJ, Reaven PD, Investigators VADT (2018) Advanced glycation end products, oxidation products, and incident cardiovascular events in patients with type 2 diabetes. Diabetes Care 41:570–576CrossRef

40.

Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107:1058–1070CrossRef

41.

Kataoka Y, Hosoda K, Makino H, Matsubara M, Matsuo M, Ohata Y, Koezuka R, Tamanaha T, Tomita T, Honda-Kohmo K, Noguchi M, Son C, Nishimura K, Asaumi Y, Miyamoto Y, Noguchi T, Yasuda S (2019) The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL). Cardiovasc Diagn Ther 9:431–438CrossRef

42.

Fujii K, Kubo T, Otake H, Nakazawa G, Sonoda S, Hibi K, Shinke T, Kobayashi Y, Ikari Y, Akasaka T (2022) Expert consensus statement for quantitative measurement and morphological assessment of optical coherence tomography: update 2022. Cardiovasc Interv Ther. https://doi.org/10.1007/s12928-022-00845-3CrossRefPubMed

Titel: Relation of glucose variability to vulnerable plaque formation in patients with coronary artery disease
verfasst von: Kazuya Tateishi
Yuichi Saito
Hideki Kitahara
Yoshio Kobayashi
Publikationsdatum: 30.03.2022
Verlag: Springer Japan
Erschienen in: Heart and Vessels / Ausgabe 9/2022
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-022-02063-6

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Assessment of sex differences in associations between sleep duration and lipid/glucose metabolism in urban Japan: a cross-sectional study

Angiotensin II inhibition increases diuresis during acute sympathetic activation in intact and denervated kidneys in rats with chronic myocardial infarction

Discharge disposition and 1-year readmission in acute-phase hospitalized patients with heart failure: a retrospective observational multi-center study

Prediction of type 4a myocardial infarction with the angiography-derived hemodynamic (ADDED) index